Business Context and Reporting Period
Company: Amesite Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 27, 2026
Reporting Period: Events occurring on April 27, 2026, with closing expected April 28, 2026.
Context: The Company entered into material definitive agreements to raise capital through a Registered Direct offering, a concurrent Private Placement (PIPE), and an Insider-Led Private Placement. The primary objective is to regain compliance with Nasdaq's minimum stockholders' equity requirement.
Key Financial Metrics and Transaction Details
- Registered Direct Offering: Sale of 696,866 shares of Common Stock at $1.435 per share.
- Private Placement (PIPE): Sale of 696,866 Pre-Funded Warrants (exercisable at $0.001) plus Series A-1 and A-2 Warrants to purchase 1,393,732 shares each. Combined price: $1.434 per unit.
- Insider-Led Private Placement: Sale of 418,118 shares of Common Stock plus Series A-1 and A-2 Warrants to purchase 418,118 shares each to officers and directors. Combined price: $1.435 per unit.
- Expected Gross Proceeds: Approximately $2.0 million from the Registered Direct and PIPE; approximately $0.6 million from the Insider-Led Private Placement.
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee on gross proceeds. Additional warrants issued to the agent (H.C. Wainwright & Co., LLC) to purchase up to 48,780 shares (RD) and 48,781 shares (PIPE) at $1.7938 per share.
- Use of Proceeds: Working capital and general corporate purposes.
- Projected Equity: Post-closing stockholders' equity is expected to exceed $2.5 million.
Material Changes and Compliance Status
The filing discloses a material change in the Company's capital structure and liquidity position. Prior to this transaction, the Company was at risk of delisting due to non-compliance with Nasdaq's minimum stockholders' equity requirement. The Company states that upon completion of the offerings, it expects to regain compliance with the $2.5 million equity threshold. The Company is currently awaiting Nasdaq's formal determination of compliance.
Outlook, Risks, and Contingencies
- Delisting Risk: If the Company fails to evidence compliance with Nasdaq's stockholders' equity requirement in its next periodic report, it may be subject to delisting.
- Warrant Terms: Common Warrants are exercisable only after stockholder approval. They contain beneficial ownership limitations (4.99% cap, waivable to 9.99%) and may be exercised on a cashless basis if no effective registration statement is available.
- Registration Rights: The Company agreed to file a Resale Registration Statement within 15 days and use best efforts to have it declared effective within 30 days (or 60 days if a full review is required).
- Unregistered Sales: Pre-Funded Warrants, Common Warrants, and Placement Agent Warrants were sold without registration under the Securities Act of 1933, relying on Section 4(a)(2) and Rule 506 exemptions.
Investor Verification Checklist
- Verify the closing date of the offerings (expected April 28, 2026) and confirmation of fund receipt.
- Confirm Nasdaq's official determination regarding the Company's regained compliance with stockholders' equity requirements.
- Monitor the filing and effectiveness of the Resale Registration Statement for the PIPE shares and Warrant Shares.
- Review the terms of the beneficial ownership limitations on Warrants and potential waivers by institutional investors.
- Assess the dilution impact of the Pre-Funded Warrants and Common Warrants upon exercise.